Literature DB >> 17047260

Dosimetric verification in participating institutions in a stereotactic body radiotherapy trial for stage I non-small cell lung cancer: Japan clinical oncology group trial (JCOG0403).

Teiji Nishio1, Etsuo Kunieda, Hiroki Shirato, Satoshi Ishikura, Hiroshi Onishi, Kunihiko Tateoka, Masahiro Hiraoka, Yuichirou Narita, Masataka Ikeda, Tomonori Goka.   

Abstract

A multicentre phase II trial of stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer was initiated in Japan as the Japan Clinical Oncology Group trial (JCOG0403). Before starting the trial, a decision was made to evaluate the treatment machine and treatment planning in participating institutions to minimize the variations of the prescription dose between the institutions. We visited the 16 participating institutions and examined the absolute dose at the centre of a simulated spherical tumour of 3.0 cm diameter in the lung using the radiation treatment planning systems in each institution. A lung phantom for stereotactic body radiotherapy (SBRT) was developed and used for the treatment planning and film dosimetry. In the JCOG radiotherapy study group, the no model-based calculation algorithm or the model-based calculation algorithm with a dose kernel unscaled for heterogeneities were selected for use in the initial SBRT trials started in 2004, and the model-based calculation algorithm with a dose kernel scaled for heterogeneities was selected for the coming trial. The findings of this study suggest that the clinical results of lung SBRT trials should be carefully evaluated in comparison with the actual dose given to patients.

Entities:  

Mesh:

Year:  2006        PMID: 17047260     DOI: 10.1088/0031-9155/51/21/002

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  14 in total

1.  Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Ryuji Mikami; Hidetugu Nakayama; Akira Sakurada; Shinji Sugahara; Kiyoshi Koizumi; Koichi Tokuuye
Journal:  Br J Radiol       Date:  2017-04-06       Impact factor: 3.039

2.  Simulation for improvement of system sensitivity of radiochromic film dosimetry with different band-pass filters and scanner light intensities.

Authors:  Takeshi Kamomae; Yuki Miyabe; Akira Sawada; Osamu Matoba; Manabu Nakata; Shinsuke Yano; Toru Takakura; Takashi Mizowaki; Akio Itoh; Masahiro Hiraoka
Journal:  Radiol Phys Technol       Date:  2011-03-17

Review 3.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer.

Authors:  Hideomi Yamashita; Wataru Takahashi; Akihiro Haga; Keiichi Nakagawa
Journal:  World J Radiol       Date:  2014-09-28

4.  Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy.

Authors:  Hideomi Yamashita; Shino Kobayashi-Shibata; Atsuro Terahara; Kae Okuma; Akihiro Haga; Reiko Wakui; Kuni Ohtomo; Keiichi Nakagawa
Journal:  Radiat Oncol       Date:  2010-05-09       Impact factor: 3.481

5.  Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202.

Authors:  Naoko Sanuki-Fujimoto; Satoshi Ishikura; Kazushige Hayakawa; Kaoru Kubota; Yutaka Nishiwaki; Tomohide Tamura
Journal:  Radiat Oncol       Date:  2009-06-02       Impact factor: 3.481

6.  An overview of the medical-physics-related verification system for radiotherapy multicenter clinical trials by the Medical Physics Working Group in the Japan Clinical Oncology Group-Radiation Therapy Study Group.

Authors:  Teiji Nishio; Mitsuhiro Nakamura; Hiroyuki Okamoto; Satoshi Kito; Toshiyuki Minemura; Shuichi Ozawa; Yu Kumazaki; Masayori Ishikawa; Naoki Tohyama; Masahiko Kurooka; Takeo Nakashima; Hidetoshi Shimizu; Ryusuke Suzuki; Satoshi Ishikura; Yasumasa Nishimura
Journal:  J Radiat Res       Date:  2020-11-16       Impact factor: 2.724

7.  Design, development of water tank-type lung phantom and dosimetric verification in institutions participating in a phase I study of stereotactic body radiation therapy in patients with T2N0M0 non-small cell lung cancer: Japan Clinical Oncology Group trial (JCOG0702).

Authors:  Teiji Nishio; Hiroki Shirato; Masayori Ishikawa; Yuki Miyabe; Satoshi Kito; Yuichirou Narita; Rikiya Onimaru; Satoshi Ishikura; Yoshinori Ito; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2014-01-01       Impact factor: 2.724

8.  Dosimetric evaluation of the impacts of different heterogeneity correction algorithms on target doses in stereotactic body radiation therapy for lung tumors.

Authors:  Masaru Narabayashi; Takashi Mizowaki; Yukinori Matsuo; Mitsuhiro Nakamura; Kenji Takayama; Yoshiki Norihisa; Katsuyuki Sakanaka; Masahiro Hiraoka
Journal:  J Radiat Res       Date:  2012-07-13       Impact factor: 2.724

9.  Developing and evaluating stereotactic lung RT trials: what we should know about the influence of inhomogeneity corrections on dose.

Authors:  Danny Schuring; Coen W Hurkmans
Journal:  Radiat Oncol       Date:  2008-07-28       Impact factor: 3.481

10.  Correlation between target volume and electron transport effects affecting heterogeneity corrections in stereotactic body radiotherapy for lung cancer.

Authors:  Yuichi Akino; Indra J Das; Higinia R Cardenes; Colleen M Desrosiers
Journal:  J Radiat Res       Date:  2014-02-11       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.